Multiple myeloma (MM) is a malignant disease characterized by the clonal proliferation of plasma cells within the bone marrow. Several cytokines have been demonstrated to be involved in the control of growth, progression, and dissemination of MM. We determined serum levels of interleukin-1beta (IL-1beta), soluble interleukin-2 receptor (sIL-2R), interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-alpha), and C-reactive protein (CRP) in 14 newly diagnosed MM patients. The median age of the patients was 63.4 +/- 10.8 years and all of the patients were stage III (classified according to the Durie-Salmon classification). The same parameters were measured in 15 healthy controls. In addition, we also examined the effects of vincristine-adriamycin-dexamethasone (VAD) therapy on the same parameters and mediators as well as the relationship among the parameters in the same patient groups. The serum concentrations of TNF-alpha, IL-1beta, sIL-2R, IL-6, IL-8, and CRP (18.6 +/- 3.7 pg/mL, 10.1 +/- 2.8 pg/mL, 730 +/- 220 U/mL, 11.4 +/- 3.3 pg/mL, 23.9 +/- 8.3 pg/mL, and 49.9 +/- 19.5 mg/dL, resp) were significantly higher in newly diagnosed MM patients than in healthy controls (P < .0001). All of the parameters were found to be significantly reduced after chemotherapy. In conclusion, we found that after the VAD therapy, the level of these cytokines which are thought to play an important role in the pathogenesis of MM was significantly suppressed. This is the first study demonstrating strong impact of VAD treatment on circulating mediators of sIL-2R and IL-8 levels parameters.
Noduler lenfosit baskin Hodgkin Lenfoma (NLBHL) nadir gorulen bir Hodgkin Lenfoma alt tipidir. Genel olarak saldirgan bir seyir gostermeyen hastalik, siklikla periferal lenfadenomegaliler disinda asemptomatiktir. Hodgkin Lenfoma gibi Cots-Wolds modifikasyonuyla Ann-Arbor evreleme sistemine gore evrelenir. Tedavide kemoterapi ve radyoterapi ya da bunlarin kombinasyonlari kullanilabilir. Bu derlemede NLBHL'nin calismalar esliginde tedavisinden bahsedecegiz.
Background: Chemotherapy-induced nephrotoxicity is an important handicap for optimal treatment. For this reason, we need useful markers for early detection of chemotherapy-induced renal disfunction. This study was performed to investigate the relationship between the plasma natriuretic peptides’ (ANP and BNP) levels and chemotherapy-induced nephrotoxicity. Methods: Thirty patients treated with cisplatin, cyclophosphamide, doxorubicin and cytosine arabinoside which having known nephrotoxic side effects, were enrolled in this study. Seventeen of the patients were male and 13 were female with a median age of 44. Also 30 healthy person were included to this study. Four chemotherapy courses were administered to each patient. Renal function tests (BUN, creatinin, urine micrototal protein/creatinin [ Pr / Cr] , glomeruler filtration rate (GFR) and urine Na) and plasma levels of ANP and BNP were measured before and after the treatments in both the patient and the control group. Results: Before the treatment, there was no significant difference between the patients and the control group in comparison of renal function tests and plasma ANP-BNP levels. However, a decline in GFR, increase in urine Pr / Cr and plasma ANP-BNP levels were observed with subsequent courses of chemotherapy protocol, which were considered statistically significant (P < 0.001). The plasma levels of ANP and BNP appeared to be higher in patients treated with nephrotoxic anticancer agents. Conclusions: The elevated levels of natriuretic peptides may be useful in determining the chemotherapy-induced nephrotoxicity earlier, which highlights their importance and role in follow-up. doi:10.4021/wjnu7e
